21 November 2017	PM: Heidelberg Pharma AG raises approximately EUR 34.4 million from capital measure	PDF	Read More
16 November 2017	AH: Heidelberg Pharma AG announces subscription price for new shares and conversion price for convertible bonds from ongoing capital measure	PDF	Read More
13 November 2017	PR: Heidelberg Pharma AG announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting	PDF	Read More
03 November 2017	AH: Heidelberg Pharma AG plans capital measure to fund its ATAC development programs	PDF	Read More
26 October 2017	Heidelberg Pharma AG: Partner RedHill Announces Orphan Drug Designation for MESUPRON	PDF	Read More
19 October 2017	PR: WILEX AG successfully completes change of name to Heidelberg Pharma AG	PDF	Read More
09 October 2017	AH: WILEX AG announces adjustment of guidance	PDF	Read More
09 October 2017	PR: WILEX AG: Interim management statement for the first nine months of 2017	PDF	Read More
26 September 2017	PR: WILEX AG: subsidiary Heidelberg Pharma becomes Runner Up in the category Best New Drug Developer at Annual World ADC Award 2017	PDF	Read More
20 September 2017	PR: WILEX AG: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit	PDF	Read More
13 July 2017	PR: WILEX reports first half 2017 results	PDF	Read More
19 June 2017	PR: WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates	PDF	Read More
19 June 2017	AH: WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates	PDF	Read More
11 May 2017	PR: WILEX AG successfully completes rights issue	PDF	Read More
24 April 2017	AH: WILEX AG plans rights issue using authorised capital	PDF	Read More
12 April 2017	PR: WILEX AG: Interim management statement on the first three months of 2017	PDF	Read More
30 March 2017	PR: WILEX announces financial figures for the 2016 fiscal year and reports on course of business	PDF	Read More
06 February 2017	AH: WILEX AG secures financing commitment from its main shareholder dievini	PDF	Read More
25 January 2017	PR: WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement	PDF	Read More
16 January 2017	AH: WILEX Signs Antibody License Agreement with Telix Pharmaceuticals Limited	PDF	Read More
16 January 2017	PR: WILEX Signs Antibody License Agreement with Telix Pharmaceuticals Limited	PDF	Read More
26 October 2016	PR: WILEX AG: Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC)	PDF	Read More
13 October 2016	PR: WILEX AG: Interim Management Statement on the First Nine Months of 2016	PDF	Read More
11 October 2016	AH: WILEX AG secures further financing with shareholder loan based on an existing financing commitment	PDF	Read More
27 September 2016	PR: WILEX AG: Subsidiary Heidelberg Pharma contracts Suisse CDMO Celonic for antibody cell line development and antibody production	PDF	Read More
19 September 2016	PR: WILEX AG: Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center	PDF	Read More
14 July 2016	PR: WILEX publishes Half-yearly Financial Report	PDF	Read More
28 June 2016	PR: WILEX AG: European Patent Office grants patent for the chemical synthetic building block dihydroxyisoleucine for the production of Amanitin	PDF	Read More
14 June 2016	PM: Advanced Proteome Therapeutics Corporation and WILEX subsidiary Heidelberg Pahrma collaborate to create improve cancer therapeutics	PDF	Read More
02 June 2016	AH: WILEX AG announces change on the Executive Management Board	PDF	Read More

Press Releases and Ad-hoc Announcements